Universal vs. ASCO guidelines-based germline genetic testing for newly diagnosed breast cancer patients in resource-restricted settings
Applying universal GGT for all newly diagnosed breast cancer patients, regardless of their age or risk factors, would slightly increase the pool of eligible patients, the burden of which can be justified given its impact on improving referral rate.
Authors
- Faris Tamimi (ORCID: https://orcid.org/0000-0002-9337-6618)
- Suhaib Khater
- Hira Bani Hani (ORCID: https://orcid.org/0009-0001-3604-0886)
- Marwa Sh Abrahim
- Sarah Abdel-Razeq (ORCID: https://orcid.org/0009-0004-0868-8919)
- Hala Abu-Jaish
- Tamer Al-Batsh
- Mohammad Sammour
- Hikmat Abdel-Razeq
- Lulwa El Saket
- Hanan Khalil
- Asem Mansour
- Baha Sharaf
Institutions
- University of Jordan (JO)
- King Hussein Cancer Center (JO)
Publication Details
- Journal
- Oncology Reviews
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/or.2025.1638255
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00